MPTP Mouse Model of Parkinson’s Disease
Target dopaminergic cell loss in the inducible MPTP Mouse Model of Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disorder that affects the motor systems in early stages, leading to symptoms such as trembling, slowing of movement, and muscle stiffness. The distinct disease mechanism can be modelled in different mouse models of PD. Degeneration of dopaminergic cells in the substantia nigra (SN) is the primary cause of the motor symptoms in PD. Administration of the MPTP, a pro-drug for the neurotoxin MPP+, selectively induces dopaminergic cell toxicity in the SN, representing one of the most widely used mouse PD models.
InnoSer offers unique services using several inducible in vivo PD models, including MPTP-based PD models. In-house validation experiments show that MPTP-induced PD models show loss of dopaminergic SN neurons, motor impairment, and activation of the NLRP3 inflammasome. As different MPTP dosing regimens lead to distinct neurodegenerative phenotypes; the choice of the model depends on your experimental compound’s hypothesized mechanism of action and research goals.
Take advantage of InnoSer’s expertise, flexibility and collaborative approach for your research. Our in-house neurology experts have long standing experience with modelling PD in vivo and are help guide your decision on choosing the best model fit for your current research goals.
InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types ranging from small molecules, peptides, enzymes, oligonucleotides, gene therapy (viral vectors – e.g.. AAVs) and immunotherapies (antibody/vaccine immunotherapies).
Key features of MPTP mouse model of Parkinson’s Disease:
- Acute and (sub)chronic varying dosing regimens possible, leading to distinct phenotypes.
- Dopaminergic neuronal loss documented in the SN.
- Motor impairments.
- Neuroinflammation (e.g., NLRP3 inflammasome activation).
- Suitable for testing anti-neuroinflammatory and neuroprotective compounds.
Find the right model for you.
Compare our model capabilities and discover which of our neurology platforms suits your research needs
Key readouts in the MPTP mouse model of Parkinson’s disease
Test the efficacy of your treatments in the following battery of behavioural tests:
- (Digital) histopathology
- Immunohistochemistry (dopamine neurons, neuroinflammation)
- Immunofluorescence and FISH
Example data featuring the MPTP mouse model of Parkinson’s disease
Test the efficacy of your treatments in the following battery of behavioural tests:
MPTP administration induces Parkinson’s disease-like phenotype which can be rescued following a treatment with a neuroprotectant
The activity of mice was tracked in their automated home-cage (PhenoTyper ™) before and after acute MPTP administration. Mice display a variety of spontaneous behaviours in our automated home-cages (PhenoTyper), which are tracked at high resolution with video cameras and do not require human intervention.
MPTP administration leads to NLRP3 inflammasome activation in the substantia nigra (SN), as detected by fluorescence immunohistochemistry (IHC)
Related Parkinson’s Disease Mouse Model options
Neurology Platform Overview
Transgenic Alpha-Synuclein Models
Seeding Alpha-Synuclein Models
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.